中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study

文献类型：期刊论文

作者Bachy, Emmanuel27,28; Savage, Kerry J.26; Huang, Huiqiang25; Kwong, Yok-Lam24; Gritti, Giuseppe23; Zhang, Qingyuan22; Liberati, Anna Marina21; Cao, Junning20; Yang, Haiyan19; Hao, Siguo18
刊名BLOOD ADVANCES
出版日期2023-08-22
卷号7
ISSN号2473-9529
DOI10.1182/bloodadvances.2022009575
通讯作者Zinzani, Pier Luigi(pierluigi.zinzani@unibo.it)
英文摘要Patients with relapsed/refractory (R/R) mature T-and natural killer (NK)-cell neoplasms lack effective treatments after failure of standard therapies. This phase 2 study evaluated the efficacy and safety of the programmed cell death protein 1 inhibitor tislelizumab in these patients. Seventy-seven patients were treated with 200 mg tislelizumab every 3 weeks. Twenty-two patients with extranodal NK-/T-cell lymphomas were enrolled in cohort 1; 44 patients with peripheral T-cell lymphoma (PTCL) were enrolled in cohort 2 (21 patients had PTCL not otherwise specified, 11 patients had angioimmunoblastic T-cell lymphoma, and 12 patients had anaplastic large-cell lymphoma). Cohort 3 comprised 11 patients with cutaneous T-cell lymphoma, of which 8 patients had mycosis fungoides (MF) and 3 had S e & PRIME;zary syndrome. Of the 77 patients, 76.6% had advanced-stage disease, 51.9% had refractory disease, and 49.4% received & GE;3 prior systemic regimens. Promising efficacy was observed in cohort 3 (median follow-up [FU], 16.6 months; overall response rate [ORR], 45.5%; complete response [CR], 9.1%; median duration of response [DOR], 11.3 months; median progression -free survival, 16.8 months; median overall survival, not reached). Modest efficacy was observed in cohort 1 (median FU, 8.4 months; ORR, 31.8%; CR, 18.2%; median DOR, not reached) and cohort 2 (median FU, 9.3 months; ORR, 20.5%; CR, 9.1%; median DOR, 8.2 months). Most treatment-related adverse events were grade 1 or 2, and the safety profile was consistent with the known safety profile of tislelizumab. In conclusion, tislelizumab was well tolerated, achieving modest efficacy in R/R mature T-and NK-cell neoplasms, with some long-lasting remissions. This trial was registered at www.clinicaltrials.gov as #NCT03493451.
WOS关键词MYCOSIS-FUNGOIDES ; RESPONSE CRITERIA ; HODGKIN-LYMPHOMA ; SEZARY-SYNDROME ; PD1 BLOCKADE ; III TRIAL ; SURVIVAL ; PROGRESSION ; NIVOLUMAB ; PD-1
资助项目BeiGene Co., Ltd. ; BeiGene
WOS研究方向Hematology
语种英语
出版者ELSEVIER
WOS记录号WOS:001063440100001
资助机构BeiGene Co., Ltd. ; BeiGene
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/132594]  
专题中国科学院合肥物质科学研究院
通讯作者Zinzani, Pier Luigi
作者单位1.Univ Bologna, Dipartimento Medicina Specialist Diagnost Speri, Bologna, Italy
2.IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy
3.BeiGene USA Inc, San Mateo, CA USA
4.BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
5.Osped Policlin San Martino, Genoa, Italy
6.Peking Univ Third Hosp, Beijing, Peoples R China
7.Peking Union Med Coll Hosp, Beijing, Peoples R China
8.Beijing Hosp, Beijing, Peoples R China
9.Inst dHematol Basse Normandie, Caen, France
10.IRCCS San Raffaele Sci Inst, Lymphoma Unit, Milan, Italy
推荐引用方式
GB/T 7714		 Bachy, Emmanuel,Savage, Kerry J.,Huang, Huiqiang,et al. Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study[J]. BLOOD ADVANCES,2023,7.
APA Bachy, Emmanuel.,Savage, Kerry J..,Huang, Huiqiang.,Kwong, Yok-Lam.,Gritti, Giuseppe.,...&Zinzani, Pier Luigi.(2023).Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.BLOOD ADVANCES,7.
MLA Bachy, Emmanuel,et al."Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study".BLOOD ADVANCES 7(2023).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。